Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Annexon Inc (ANNX)

Annexon Inc (ANNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MarketBeat.com
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout MarketBeat - Thu Jun 4, 2:07AM CDT

Annexon (NASDAQ:ANNX) executives outlined a series of expected clinical and regulatory updates across the company’s complement-focused pipeline during a session at the Jefferies Conference, highlighting...

ANNX : 4.71 (+0.21%)
Annexon to Participate in Upcoming June Investor Conferences GlobeNewswire - Wed May 27, 7:00AM CDT

BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc.  (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 4.71 (+0.21%)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon May 18, 3:05PM CDT

BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 4.71 (+0.21%)
MarketBeat.com
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference MarketBeat - Thu May 14, 3:05AM CDT

Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company’s late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcoming...

ANNX : 4.71 (+0.21%)
Annexon: The Cash Runway Question Looms Larger Than the Pipeline Update Barchart - Fri May 8, 4:01PM CDT

Barchart Research What to Expect from ANNX Earnings ANNX Generated May 8, 2026 Current Price $5.69 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 5.14% Annexon: The Cash Runway Question...

ANNX : 4.71 (+0.21%)
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones GlobeNewswire - Thu May 7, 3:01PM CDT

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing Authorization...

ANNX : 4.71 (+0.21%)
Annexon to Present at the Bank of America Securities Health Care Conference 2026 GlobeNewswire - Wed May 6, 7:00AM CDT

BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 4.71 (+0.21%)
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference GlobeNewswire - Wed Apr 8, 3:05PM CDT

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 4.71 (+0.21%)
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones GlobeNewswire - Mon Mar 30, 3:01PM CDT

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with...

ANNX : 4.71 (+0.21%)
Annexon Has Been Quietly Building Toward This Moment. Investors Are About to Find Out If It Was Enough. Barchart - Sun Mar 29, 4:00PM CDT

Barchart Research What to Expect from ANNX Earnings ANNX Generated March 27, 2026 Current Price $5.00 EPS Estimate $-0.32 Consensus Rating Strong Buy Average Move 5.49% Annexon Has Been Quietly Building...

ANNX : 4.71 (+0.21%)

Barchart Exclusives

Dear Applied Digital Stock Fans, Mark Your Calendars for June 16 Barchart - Sat Jun 13, 2:30PM CDT
Applied Digital has announced a senior secured note offering of $1.59 billion for funding its Polaris Forge 1 expansion. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.